RV
RVP.US Retractable Technologies Inc
- Market cap
- USD 16.9M
- P/E
- -
- P/B
- 0.23x
- ROE
- -7.1%
- Dividend yield
- 1.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RVP.US undervalued?
Graham numberThe Graham number of Retractable Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Retractable Technologies Inc fundamental analysis
No fundamental analysis for Retractable Technologies Inc yet.
Retractable Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Retractable Technologies Inc
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint b…
Full company profileRetractable Technologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Retractable Technologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 29.8M | 34.5M | 33.3M | 41.8M | 81.9M | 188M | 94.8M | 43.6M | 33.0M | 38.3M | 38.0M |
| Gross Profit | 10.3M | 9.97M | 10.2M | 14.1M | 37.0M | 95.4M | 28.3M | 9.11M | -1.03M | 47.0K | 545K |
| Operating Income | -3.51M | -3.78M | -1.32M | 2.97M | 24.1M | 72.6M | -853K | -11.5M | -21.1M | -20.2M | -20.6M |
| EBITDA | -2.61M | -2.88M | -289K | 4.18M | 27.2M | 76.4M | 9.94M | -1.24M | 4.17M | -4.42M | -2.25M |
| Net Income | -3.69M | -3.74M | -1.34M | 3.15M | 24.2M | 56.1M | 5.08M | -7.01M | -11.9M | -12.6M | -5.01M |
| EPS | -0.13 | -0.12 | -0.04 | 0.10 | 0.73 | 1.64 | 0.15 | -0.23 | -0.40 | -0.42 | -0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 38.8M | 38.2M | 36.8M | 45.8M | 105M | 213M | 211M | 180M | 161M | 143M | 139M |
| Total Liabilities | 10.7M | 11.0M | 11.2M | 17.3M | 55.1M | 114M | 104M | 80.4M | 73.6M | 68.3M | 68.1M |
| Shareholders' Equity | 28.1M | 27.2M | 25.6M | 28.5M | 49.9M | 99.2M | 107M | 99.3M | 87.2M | 74.4M | 70.4M |
| Cash & Short-term Investments | 16.2M | 14.9M | 10.6M | 13.7M | 25.6M | 42.4M | 49.4M | 47.3M | 44.6M | 37.0M | 1.89M |
| Total Debt | 3.93M | 3.49M | 3.05M | 2.72M | 3.74M | 4.24M | 2.92M | 1.54M | 1.23M | 896K | 386K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -795K | -2.92M | -1.20M | 2.19M | 19.0M | 32.8M | 16.8M | 2.77M | -11.6M | -7.06M | -4.46M |
| Capital Expenditure | 1.95M | 91.9K | 382K | 632K | 21.0M | 58.4M | 16.8M | 853K | 1.44M | 536K | 119K |
| Free Cash Flow | -2.74M | -3.01M | -1.58M | 1.56M | -2.05M | -25.6M | -61.9K | 1.91M | -13.0M | -7.60M | -4.58M |
| Ratios | |||||||||||
| ROE | -13.1% | -13.7% | -5.2% | 11.0% | 48.6% | 56.5% | 4.8% | -7.1% | -13.6% | -16.9% | -7.1% |
| ROA | -9.5% | -9.8% | -3.6% | 6.9% | 23.1% | 26.3% | 2.4% | -3.9% | -7.4% | -8.8% | -3.6% |
| Net Profit Margin | -12.4% | -10.8% | -4.0% | 7.5% | 29.6% | 29.8% | 5.4% | -16.1% | -36.0% | -32.8% | -13.2% |
| Debt to Equity | 0.14x | 0.13x | 0.12x | 0.10x | 0.08x | 0.04x | 0.03x | 0.02x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Retractable Technologies Inc dividends
- Dividend yield
- 1.36%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 230K | 0.01 | - |
| 2024 | USD 230K | 0.01 | - |
| 2023 | USD 232K | 0.01 | - |
| 2022 | USD 253K | 0.01 | 5.0% |
| 2021 | USD 3.82M | 0.11 | 6.8% |
| 2020 | USD 217K | 0.01 | 0.9% |
| 2019 | USD 220K | 0.01 | 7.0% |
| 2018 | USD 220K | 0.01 | - |
| 2017 | USD 220K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Retractable Technologies Inc
- Insiders 59.23%
- Institutions 8.32%
- Public & others 32.45%
- Shares outstanding 29.9M
- Free float 12.2M
Retractable Technologies Inc company profile
- Company name
- Retractable Technologies Inc
- Ticker
- RVP.US
- Exchange
- USA Stocks
- Listed since
- May 4, 2001
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 195
- Fiscal year end
- December
- Address
- 511 Lobo Lane, Little Elm, TX, United States, 75068-5295
- Phone
- 972 294 1010
- Website
- retractable.com
About Retractable Technologies Inc
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and national direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
Retractable Technologies Inc management
4- Mr. Thomas J. ShawFounder, Chairman, President & CEO · born 1951
- Mr. John W. Fort IIIVP, CFO, Principal Accounting Officer,Treasurer & Director · born 1969
- Mr. Lawrence G. SalernoDirector of Operations · born 1960
- Ms. Michele M. Larios Esq.VP, General Counsel & Secretary · born 1966